Control Of Organ Transplant-Associated Graft-versus-Host Disease By Activated Host Lymphocyte Infusions

Authors:
  • MTMatthias Theobald
    Matthias Theobald
  • EFEdite Antunes Ferreira
    Edite Antunes Ferreira
  • GHGeorg Hess
    Georg Hess
  • JBJürgen Burg
    Jürgen Burg
  • GMGiancarlo Maccagno
    Giancarlo Maccagno
  • ABAna P Barreiros
    Ana P Barreiros
  • CSCarl C Schimanski
    Carl C Schimanski
  • MSMarkus Schuchmann
    Markus Schuchmann
  • ASAndreas Schwarting
    Andreas Schwarting
  • MNMarkus Neurath
    Markus Neurath

Abstract
Prolonged persistence of donor-derived T cells after organ transplantation has been proposed to improve long-term allograft survival. However, surviving transplant-derived T cells are also able to mediate devastating graft-versus-host disease (GvHD). Currently, GvHD after organ transplantation is usually refractory to conventional therapy and the disease outcome fatal. Graft-reactive host T cells were generated ex vivo from a patient suffering from a severe and refractory liver–transplant-associated GvHD. To control GvHD, activated alloreactive host T cells were repetitively retransferred into the patient (activated host lymphocyte infusion [aHLI]). Adoptive transfer of ex vivo activated alloreactive host T cells (aHLI) led to the control and complete resolution of severe GvHD without inducing allograft rejection. aHLI opens a novel therapeutic window to control solid-organ transplant-associated GvHD while preserving allograft integrity.

This publication has 28 references indexed in Scilit: